Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
TARO's Cash to Debt is ranked higher than
98% of the 791 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. TARO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
TARO' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 2.28 Max: No Debt
Current: No Debt
Equity to Asset 0.89
TARO's Equity to Asset is ranked higher than
91% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TARO: 0.89 )
Ranked among companies with meaningful Equity to Asset only.
TARO' s Equity to Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.55 Max: 0.89
Current: 0.89
0.23
0.89
Interest Coverage 58.44
TARO's Interest Coverage is ranked lower than
56% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. TARO: 58.44 )
Ranked among companies with meaningful Interest Coverage only.
TARO' s Interest Coverage Range Over the Past 10 Years
Min: 2.59  Med: 207.4 Max: N/A
Current: 58.44
F-Score: 5
Z-Score: 13.58
M-Score: -0.74
WACC vs ROIC
4.18%
34.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 62.75
TARO's Operating margin (%) is ranked higher than
99% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.69 vs. TARO: 62.75 )
Ranked among companies with meaningful Operating margin (%) only.
TARO' s Operating margin (%) Range Over the Past 10 Years
Min: 13.31  Med: 40.49 Max: 64.63
Current: 62.75
13.31
64.63
Net-margin (%) 51.51
TARO's Net-margin (%) is ranked higher than
98% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. TARO: 51.51 )
Ranked among companies with meaningful Net-margin (%) only.
TARO' s Net-margin (%) Range Over the Past 10 Years
Min: 9.28  Med: 36.13 Max: 56.9
Current: 51.51
9.28
56.9
ROE (%) 25.64
TARO's ROE (%) is ranked higher than
88% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. TARO: 25.64 )
Ranked among companies with meaningful ROE (%) only.
TARO' s ROE (%) Range Over the Past 10 Years
Min: 19.01  Med: 35.37 Max: 49.88
Current: 25.64
19.01
49.88
ROA (%) 22.56
TARO's ROA (%) is ranked higher than
95% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. TARO: 22.56 )
Ranked among companies with meaningful ROA (%) only.
TARO' s ROA (%) Range Over the Past 10 Years
Min: 6.38  Med: 27.02 Max: 32.05
Current: 22.56
6.38
32.05
ROC (Joel Greenblatt) (%) 52.40
TARO's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. TARO: 52.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TARO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.67  Med: 61.16 Max: 109.38
Current: 52.4
17.67
109.38
Revenue Growth (3Y)(%) 13.90
TARO's Revenue Growth (3Y)(%) is ranked higher than
73% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. TARO: 13.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TARO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 11.8 Max: 34.7
Current: 13.9
0
34.7
EBITDA Growth (3Y)(%) 24.10
TARO's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.00 vs. TARO: 24.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TARO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 26.7 Max: 55.9
Current: 24.1
0
55.9
EPS Growth (3Y)(%) 28.30
TARO's EPS Growth (3Y)(%) is ranked higher than
80% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. TARO: 28.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TARO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 28.3 Max: 104.9
Current: 28.3
0
104.9
GuruFocus has detected 1 Warning Sign with Taro Pharmaceutical Industries Ltd $TARO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

TARO Guru Trades in Q1 2016

HOTCHKIS & WILEY 148,983 sh (+8.96%)
Jim Simons 491,300 sh (+8.89%)
David Dreman 172 sh (unchged)
» More
Q2 2016

TARO Guru Trades in Q2 2016

Paul Tudor Jones 2,663 sh (New)
David Dreman 257 sh (+49.42%)
Jim Simons 620,900 sh (+26.38%)
HOTCHKIS & WILEY 151,330 sh (+1.58%)
» More
Q3 2016

TARO Guru Trades in Q3 2016

Paul Tudor Jones 7,636 sh (+186.74%)
David Dreman 414 sh (+61.09%)
Jim Simons 629,900 sh (+1.45%)
HOTCHKIS & WILEY Sold Out
» More
Q4 2016

TARO Guru Trades in Q4 2016

Paul Tudor Jones 14,160 sh (+85.44%)
Jim Simons 547,600 sh (-13.07%)
David Dreman 36 sh (-91.30%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic  
Compare:NAS:OPK, NYSE:PTHN, OTCPK:HYPMY, NYSE:VRX, NYSE:MNK, NAS:NBIX, OTCPK:STDAF, NAS:MDCO, NYSE:CTLT, OTCPK:HKMPY, OTCPK:INVVY, OTCPK:SHPHF, OTCPK:IPSEY, NAS:ENDP, NAS:HZNP, NAS:AKRX, NAS:IRWD, NYSE:RDY, NAS:RDUS, NAS:PCRX » details
Traded in other countries:TAL.Germany,
Taro Pharmaceutical Industries Ltd is a multinational, science-based pharmaceutical company. It develops manufactures and markets Rx and OTC pharmaceutical products in the United States, Canada and Israel.

Taro Pharmaceutical Industries Ltd was incorporated under the laws of the State of Israel in 1959 under the name Taro-Vit Chemical Industries Ltd. In 1984, it changed its name to Taro Vit Industries Ltd. and in 1994 it changed its name to Taro Pharmaceutical Industries Ltd., which was the name of a subsidiary of Taro Vit Industries Ltd. incorporated under the laws of the State of Israel in 1950. The Company is a multinational, science-based pharmaceutical company. It develops manufactures and markets Rx and OTC pharmaceutical products in the United States, Canada and Israel. Its primary areas of focus include semi-solids formulations such as creams and ointments and other dosage forms such as liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company markets its pharmaceutical products in many countries. The Company competes with the original manufacturers of the brand-name equivalents of its generic products, other generic drug manufacturers including brand-name companies that also manufacture generic drugs or license their products to other generic drug manufacturers and manufacturers of new drugs that may compete with its generic drugs. In Canada, the Company's competition includes Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Valeant Canada, AstraZeneca Canada, Johnson & Johnson Inc., Bayer Inc. and Bristol-Myers Squibb Canada. The Company also competes with other manufacturers of generic products, such as Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated and Pharmascience Inc. In Israel, it competes with Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexcel Pharma Israel, and Rafa Laboratories Ltd., among others. In addition, many multinational companies, including Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc., market their products in Israel. The Company's products and services are subject to pharmaceutical industry regulations in the United States, Canada, Israel and other jurisdictions, and may be subject to future legislative and other regulatory developments concerning its products and the healthcare field generally.

Top Ranked Articles about Taro Pharmaceutical Industries Ltd

Gurus' Stocks With Low P/E Ratios Some of the stocks have wide margins of safety
Gurus are buying stocks that are trading with low price-earnings (P/E) ratios. Some are greatly undervalued, according to the DCF calculator. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 9.99
TARO's P/E(ttm) is ranked higher than
93% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.03 vs. TARO: 9.99 )
Ranked among companies with meaningful P/E(ttm) only.
TARO' s P/E(ttm) Range Over the Past 10 Years
Min: 3.13  Med: 10.08 Max: 20.41
Current: 9.99
3.13
20.41
PE(NRI) 9.98
TARO's PE(NRI) is ranked higher than
92% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. TARO: 9.98 )
Ranked among companies with meaningful PE(NRI) only.
TARO' s PE(NRI) Range Over the Past 10 Years
Min: 2.84  Med: 10.11 Max: 20.41
Current: 9.98
2.84
20.41
Price/Owner Earnings (ttm) 10.76
TARO's Price/Owner Earnings (ttm) is ranked higher than
89% of the 298 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.84 vs. TARO: 10.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TARO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.5  Med: 10.22 Max: 24.34
Current: 10.76
3.5
24.34
P/B 2.40
TARO's P/B is ranked higher than
64% of the 819 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. TARO: 2.40 )
Ranked among companies with meaningful P/B only.
TARO' s P/B Range Over the Past 10 Years
Min: 1.18  Med: 2.68 Max: 6.4
Current: 2.4
1.18
6.4
P/S 5.16
TARO's P/S is ranked lower than
64% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.12 vs. TARO: 5.16 )
Ranked among companies with meaningful P/S only.
TARO' s P/S Range Over the Past 10 Years
Min: 1  Med: 3.42 Max: 9.71
Current: 5.16
1
9.71
PFCF 11.00
TARO's PFCF is ranked higher than
85% of the 223 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.98 vs. TARO: 11.00 )
Ranked among companies with meaningful PFCF only.
TARO' s PFCF Range Over the Past 10 Years
Min: 5.87  Med: 11.03 Max: 28.48
Current: 11
5.87
28.48
POCF 10.26
TARO's POCF is ranked higher than
76% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.86 vs. TARO: 10.26 )
Ranked among companies with meaningful POCF only.
TARO' s POCF Range Over the Past 10 Years
Min: 5.63  Med: 10.41 Max: 26.11
Current: 10.26
5.63
26.11
EV-to-EBIT 6.87
TARO's EV-to-EBIT is ranked higher than
94% of the 570 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.59 vs. TARO: 6.87 )
Ranked among companies with meaningful EV-to-EBIT only.
TARO' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.5  Med: 7.5 Max: 52.3
Current: 6.87
4.5
52.3
EV-to-EBITDA 6.71
TARO's EV-to-EBITDA is ranked higher than
92% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.67 vs. TARO: 6.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
TARO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4  Med: 6.65 Max: 52.3
Current: 6.71
4
52.3
Shiller P/E 20.71
TARO's Shiller P/E is ranked higher than
86% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.89 vs. TARO: 20.71 )
Ranked among companies with meaningful Shiller P/E only.
TARO' s Shiller P/E Range Over the Past 10 Years
Min: 10.73  Med: 24.77 Max: 58.09
Current: 20.71
10.73
58.09
Current Ratio 7.44
TARO's Current Ratio is ranked higher than
86% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. TARO: 7.44 )
Ranked among companies with meaningful Current Ratio only.
TARO' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.84 Max: 7.65
Current: 7.44
0.79
7.65
Quick Ratio 6.83
TARO's Quick Ratio is ranked higher than
86% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. TARO: 6.83 )
Ranked among companies with meaningful Quick Ratio only.
TARO' s Quick Ratio Range Over the Past 10 Years
Min: 0.55  Med: 1.97 Max: 7.08
Current: 6.83
0.55
7.08
Days Inventory 266.28
TARO's Days Inventory is ranked lower than
90% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.25 vs. TARO: 266.28 )
Ranked among companies with meaningful Days Inventory only.
TARO' s Days Inventory Range Over the Past 10 Years
Min: 163.69  Med: 197.98 Max: 278.28
Current: 266.28
163.69
278.28
Days Sales Outstanding 96.88
TARO's Days Sales Outstanding is ranked lower than
66% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.25 vs. TARO: 96.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
TARO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.21  Med: 68.89 Max: 94.08
Current: 96.88
63.21
94.08
Days Payable 449.72
TARO's Days Payable is ranked higher than
98% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 71.46 vs. TARO: 449.72 )
Ranked among companies with meaningful Days Payable only.
TARO' s Days Payable Range Over the Past 10 Years
Min: 38.15  Med: 48.33 Max: 69.43
Current: 449.72
38.15
69.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.50
TARO's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 440 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.20 vs. TARO: 1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TARO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.4  Med: -3.5 Max: 1.5
Current: 1.5
-10.4
1.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.85
TARO's Price/Net Cash is ranked lower than
99.99% of the 252 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.77 vs. TARO: 15.85 )
Ranked among companies with meaningful Price/Net Cash only.
TARO' s Price/Net Cash Range Over the Past 10 Years
Min: 6.83  Med: 15.36 Max: 190.55
Current: 15.85
6.83
190.55
Price/Net Current Asset Value 3.13
TARO's Price/Net Current Asset Value is ranked lower than
99.99% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. TARO: 3.13 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
TARO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.82  Med: 6.48 Max: 730.33
Current: 3.13
2.82
730.33
Price/Tangible Book 2.40
TARO's Price/Tangible Book is ranked higher than
70% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.68 vs. TARO: 2.40 )
Ranked among companies with meaningful Price/Tangible Book only.
TARO' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.89  Med: 2.43 Max: 15.98
Current: 2.4
0.89
15.98
Price/Projected FCF 0.76
TARO's Price/Projected FCF is ranked lower than
99.99% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.75 vs. TARO: 0.76 )
Ranked among companies with meaningful Price/Projected FCF only.
TARO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.69  Med: 1.8 Max: 23.54
Current: 0.76
0.69
23.54
Price/Median PS Value 1.51
TARO's Price/Median PS Value is ranked lower than
99.99% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.12 vs. TARO: 1.51 )
Ranked among companies with meaningful Price/Median PS Value only.
TARO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.75 Max: 2.58
Current: 1.51
0.11
2.58
Price/Peter Lynch Fair Value 0.40
TARO's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. TARO: 0.40 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
TARO' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.13  Med: 0.74 Max: 22.71
Current: 0.4
0.13
22.71
Price/Graham Number 1.03
TARO's Price/Graham Number is ranked lower than
99.99% of the 457 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. TARO: 1.03 )
Ranked among companies with meaningful Price/Graham Number only.
TARO' s Price/Graham Number Range Over the Past 10 Years
Min: 0.41  Med: 1.19 Max: 11.74
Current: 1.03
0.41
11.74
Earnings Yield (Greenblatt) (%) 14.60
TARO's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 838 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. TARO: 14.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TARO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 13.35 Max: 22.4
Current: 14.6
1.9
22.4
Forward Rate of Return (Yacktman) (%) 32.06
TARO's Forward Rate of Return (Yacktman) (%) is ranked higher than
89% of the 351 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.42 vs. TARO: 32.06 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TARO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -21.4  Med: 3.8 Max: 53.9
Current: 32.06
-21.4
53.9

More Statistics

Revenue (TTM) (Mil) $948.0
EPS (TTM) $ 11.68
Beta0.32
Short Percentage of Float20.44%
52-Week Range $92.28 - 152.30
Shares Outstanding (Mil)41.03
» More Articles for NYSE:TARO

Headlines

Articles On GuruFocus.com
Gurus' Stocks With Low P/E Ratios Oct 31 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
My Low-Debt List Has Shown a Profit 12 years out of 13 May 13 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 

More From Other Websites
Taro Pharmaceutical Industries Ltd. :TARO-US: Earnings Analysis: Q3, 2017 By the Numbers : February... Feb 13 2017
Taro Pharma 3Q Net $140M Versus $189M Last Year Feb 10 2017
Taro posts 3Q profit Feb 09 2017
Taro posts 3Q profit Feb 09 2017
Taro Provides Results for December 31, 2016 Feb 09 2017
Q3 2017 Taro Pharmaceutical Industries Ltd Earnings Release - After Market Close Feb 09 2017
Taro to Announce Third Quarter Results on February 9, 2017 Jan 31 2017
Perrigo's (PRGO) Generic Version of Topicort Okayed by FDA Jan 25 2017
Taro Pharmaceutical Industries Ltd. – Value Analysis (NYSE:TARO) : January 13, 2017 Jan 13 2017
Taro Pharmaceutical Industries Ltd. breached its 50 day moving average in a Bearish Manner : TARO-US... Jan 12 2017
TARO 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and... Dec 23 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Taro Pharmaceutical Industries Ltd. of... Dec 23 2016
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc Dec 23 2016
Taro Announces Sale of U.S. Rights to Keveyis® to Strongbridge Biopharma plc Dec 23 2016
GPM Reminds Investors of the December 27th Deadline in the Class Action Lawsuit Against Taro... Dec 20 2016
DEADLINE ALERT: Brower Piven Notifies Shareholders of Upcoming Deadline In Class Action Lawsuit And... Dec 20 2016
TARO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Dec 20 2016
TARO NOTICE: Rosen Law Reminds Taro Pharmaceutical Industries Ltd. Investors of Important December... Dec 19 2016
SHAREHOLDER REMINDER: Deadline in Class Action Lawsuit Filed Against Taro Pharmaceutical Industries... Dec 19 2016
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Taro... Dec 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)